VVOS
Vivos Therapeutics Inc

5,593
Mkt Cap
$17.71M
Volume
273,321.00
52W High
$7.95
52W Low
$1.98
PE Ratio
-1.26
VVOS Fundamentals
Price
$2.12
Prev Close
$2.36
Open
$2.26
50D MA
$2.94
Beta
0.67
Avg. Volume
254,555.83
EPS (Annual)
-$2.22
P/B
3.77
Rev/Employee
$137,899.08
Loading...
Loading...
News
all
press releases
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -15.56% and +14.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
More News
News Placeholder
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.69% and +107.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Zoetis (ZTS) Surpasses Q3 Earnings Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of +4.94% and -0.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +218.52% and +66.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Zacks·6mo ago
News Placeholder
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
chainwire·7mo ago
News Placeholder
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17. read more...
Benzinga·1y ago
News Placeholder
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript...
SeekingAlpha·2y ago
News Placeholder
VVOS Stock Earnings: Vivos Therapeutics Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips VVOS stock results show that Vivos Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth...
InvestorPlace·2y ago

Latest VVOS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.